| Attribute |
Value |
| 52 Week Change |
-0.09560305 |
| Address1 |
46, avenue de la Grande ArmEe |
| All Time High |
60.12 |
| All Time Low |
22.53 |
| Ask |
51.21 |
| Ask Size |
1 |
| Average Analyst Rating |
2.1 - Buy |
| Average Daily Volume10 Day |
2,189,720 |
| Average Daily Volume3 Month |
3,349,051 |
| Average Volume |
3,349,051 |
| Average Volume10Days |
2,189,720 |
| Beta |
0.277 |
| Bid |
40.0 |
| Bid Size |
20 |
| Book Value |
33.315964 |
| City |
Paris |
| Country |
France |
| Crypto Tradeable |
0 |
| Currency |
USD |
| Current Price |
44.82 |
| Current Ratio |
0.987 |
| Custom Price Alert Confidence |
HIGH |
| Date Short Interest |
1,786,665,600 |
| Day High |
44.96 |
| Day Low |
44.675 |
| Debt To Equity |
33.89 |
| Dividend Date |
1,780,444,800 |
| Dividend Rate |
2.42 |
| Dividend Yield |
5.39 |
| Earnings Call Timestamp End |
1,785,409,200 |
| Earnings Call Timestamp Start |
1,785,409,200 |
| Earnings Growth |
-0.912 |
| Earnings Quarterly Growth |
-0.913 |
| Earnings Timestamp |
1,793,363,400 |
| Earnings Timestamp End |
1,793,363,400 |
| Earnings Timestamp Start |
1,793,363,400 |
| Ebitda |
13,543,000,064 |
| Ebitda Margins |
0.27685 |
| Enterprise To Ebitda |
9.228 |
| Enterprise To Revenue |
2.555 |
| Enterprise Value |
124,980,903,936 |
| Eps Current Year |
4.98556 |
| Eps Forward |
5.38072 |
| Eps Trailing Twelve Months |
1.89 |
| Esg Populated |
0 |
| Ex Dividend Date |
1,777,852,800 |
| Exchange |
NMS |
| Exchange Data Delayed By |
0 |
| Exchange Timezone Name |
America/New_York |
| Exchange Timezone Short Name |
EDT |
| Fifty Day Average |
43.61 |
| Fifty Day Average Change |
1.2099991 |
| Fifty Day Average Change Percent |
0.027745908 |
| Fifty Two Week Change Percent |
-9.560305 |
| Fifty Two Week High |
52.68 |
| Fifty Two Week High Change |
-7.8600006 |
| Fifty Two Week High Change Percent |
-0.14920275 |
| Fifty Two Week Low |
40.89 |
| Fifty Two Week Low Change |
3.9300003 |
| Fifty Two Week Low Change Percent |
0.09611153 |
| Fifty Two Week Range |
40.89 - 52.68 |
| Financial Currency |
EUR |
| First Trade Date Milliseconds |
1,025,530,200,000 |
| Five Year Avg Dividend Yield |
4.04 |
| Float Shares |
2,160,286,185 |
| Forward Eps |
5.38072 |
| Forward P E |
8.32974 |
| Free Cashflow |
6,298,999,808 |
| Full Exchange Name |
NasdaqGS |
| Full Time Employees |
74,846 |
| Fullday Change |
-0.0200005 |
| Fullday Change Percent |
-0.0446041 |
| Fullday Price |
44.83 |
| Gmt Off Set Milliseconds |
-14,400,000 |
| Gross Margins |
0.73452 |
| Gross Profits |
35,932,000,256 |
| Has Pre Post Market Data |
1 |
| Held Percent Insiders |
0.000010000001 |
| Held Percent Institutions |
0.08016 |
| Implied Shares Outstanding |
2,396,137,370 |
| Industry |
Drug Manufacturers - General |
| Industry Disp |
Drug Manufacturers - General |
| Industry Key |
drug-manufacturers-general |
| Ir Website |
http://en.sanofi.com/investors/investors.aspx |
| Is Earnings Date Estimate |
0 |
| Language |
en-US |
| Last Dividend Date |
1,777,852,800 |
| Last Dividend Value |
2.422 |
| Last Fiscal Year End |
1,767,139,200 |
| Long Business Summary |
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France. |
| Long Name |
Sanofi |
| Market |
us_market |
| Market Cap |
107,394,883,584 |
| Market State |
CLOSED |
| Max Age |
86,400 |
| Message Board Id |
finmb_687130 |
| Most Recent Quarter |
1,782,777,600 |
| Net Income To Common |
3,939,000,064 |
| Next Fiscal Year End |
1,798,675,200 |
| Non Diluted Market Cap |
107,904,303,359 |
| Number Of Analyst Opinions |
9 |
| Open |
44.93 |
| Operating Cashflow |
11,838,000,128 |
| Operating Margins |
0.21033001 |
| Payout Ratio |
1.278 |
| Peg Ratio |
29.87 |
| Phone |
33 1 53 77 40 00 |
| Post Market Change |
0.010002136 |
| Post Market Change Percent |
0.022316234 |
| Post Market Price |
44.83 |
| Post Market Time |
1,787,959,221 |
| Previous Close |
44.84 |
| Price Eps Current Year |
8.989964 |
| Price Hint |
2 |
| Price To Book |
1.345301 |
| Price To Sales Trailing12 Months |
2.1953614 |
| Profit Margins |
0.08091 |
| Quick Ratio |
0.487 |
| Quote Source Name |
Nasdaq Real Time Price |
| Quote Type |
EQUITY |
| Recommendation Key |
buy |
| Recommendation Mean |
2.1 |
| Region |
US |
| Regular Market Change |
-0.0200005 |
| Regular Market Change Percent |
-0.0446041 |
| Regular Market Day High |
44.96 |
| Regular Market Day Low |
44.675 |
| Regular Market Day Range |
44.675 - 44.96 |
| Regular Market Open |
44.93 |
| Regular Market Previous Close |
44.84 |
| Regular Market Price |
44.82 |
| Regular Market Time |
1,787,947,200 |
| Regular Market Volume |
1,357,676 |
| Return On Assets |
0.05093 |
| Return On Equity |
0.05709 |
| Revenue Growth |
0.146 |
| Revenue Per Share |
20.2505 |
| Sand P52 Week Change |
0.20504117 |
| Sector |
Healthcare |
| Sector Disp |
Healthcare |
| Sector Key |
healthcare |
| Shares Outstanding |
2,396,137,370 |
| Shares Percent Shares Out |
0.0031 |
| Shares Short |
7,315,661 |
| Shares Short Previous Month Date |
1,784,073,600 |
| Shares Short Prior Month |
7,371,480 |
| Short Name |
Sanofi |
| Short Percent Of Float |
0.0034 |
| Short Ratio |
2.23 |
| Source Interval |
15 |
| Symbol |
SNY |
| Target High Price |
63.0 |
| Target Low Price |
45.0 |
| Target Mean Price |
53.72222 |
| Target Median Price |
54.5 |
| Total Cash |
6,350,000,128 |
| Total Cash Per Share |
2.65 |
| Total Debt |
23,576,000,512 |
| Total Revenue |
48,918,999,040 |
| Tradeable |
0 |
| Trailing Annual Dividend Rate |
4.12 |
| Trailing Annual Dividend Yield |
0.091882244 |
| Trailing Eps |
1.89 |
| Trailing P E |
23.714285 |
| Trailing Peg Ratio |
28.9008 |
| Triggerable |
1 |
| Two Hundred Day Average |
45.9578 |
| Two Hundred Day Average Change |
-1.1378021 |
| Two Hundred Day Average Change Percent |
-0.02475754 |
| Type Disp |
Equity |
| Volume |
1,357,676 |
| Website |
https://www.sanofi.com |
| Zip |
75,017 |